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Abstract
Lung	cancer	remains	the	most	 lethal	cancer	among	men	and	women	in	the	United	
States	and	worldwide.	The	majority	of	lung	cancer	cases	are	classified	as	non-small	
cell	lung	cancer	(NSCLC).	Developing	new	therapeutics	on	the	basis	of	better	under-
standing	of	NSCLC	biology	is	critical	to	improve	the	treatment	of	NSCLC.	MicroRNAs	
(miRNAs	or	miRs)	are	a	superfamily	of	genome-derived,	small	noncoding	RNAs	that	
govern	 posttranscriptional	 gene	 expression	 in	 cells.	 Functional	 miRNAs	 are	 com-
monly	dysregulated	in	NSCLC,	caused	by	genomic	deletion,	methylation,	or	altered	
processing,	which	may	lead	to	the	changes	of	many	cancer-related	pathways	and	pro-
cesses,	such	as	growth	and	death	signaling,	metabolism,	angiogenesis,	cell	cycle,	and	
epithelial	to	mesenchymal	transition,	as	well	as	sensitivity	to	current	therapies.	With	
the	understanding	of	miRNA	biology	in	NSCLC,	there	are	growing	interests	in	devel-
oping	new	therapeutic	strategies,	namely	restoration	of	tumor	suppressive	miRNAs	
and	inhibition	of	tumor	promotive	miRNAs,	to	combat	against	NSCLC.	In	this	article,	
we	provide	an	overview	on	the	molecular	features	of	NSCLC	and	current	treatment	
options	with	a	 focus	on	pharmacotherapy	and	personalized	medicine.	By	 illustrat-
ing	the	roles	of	miRNAs	in	the	control	of	NSCLC	tumorigenesis	and	progression,	we	
highlight	the	latest	efforts	in	assessing	miRNA-based	therapies	in	animal	models	and	
discuss	some	critical	challenges	in	developing	RNA	therapeutics.
K E Y W O R D S
Cancer,	miRNA,	NSCLC,	regulation,	therapy,	tumorigenesis
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1  | INTRODUCTION
Lung	and	bronchus	cancer	is	the	second	most	commonly	diagnosed	
cancer	in	the	United	States,	with	over	220,000	estimated	new	diag-
noses	in	2019,	accounting	for	almost	13%	of	all	cancer	diagnoses.1 
One	in	15	men	and	1	in	17	women	will	be	diagnosed	with	lung	cancer	
during	their	 lifetime	and	the	average	age	at	diagnosis	 is	70	years.1 
Lung	cancer	accounts	 for	 the	highest	cancer-related	deaths	 in	 the	
United	 States,	 causing	 23%	 of	 all	 cancer-related	 deaths	 which	 is	
more	than	colon,	breast,	and	prostate	cancers	combined.1	The	five-
year	survival	rate	of	all	lung	cancer	diagnoses	is	19%,	which	is	lower	
than	colon,	breast,	 and	prostate	cancers.	When	 the	disease	 is	de-
tected	while	still	localized	to	the	lung,	the	five-year	survival	rate	is	
56%;	however,	only	16%	of	cases	at	diagnosed	at	that	stage.	By	con-
trast,	the	five-year	survival	rate	for	metastatic	lung	cancer	patients	
is	only	5%.	More	than	half	of	patients	diagnosed	with	lung	cancer	will	
die within one year. It is also estimated that lung cancer care may be 
increased	to	173	billion	dollars	in	2020	in	the	United	States.2
The lung epithelium undergoes a series of morphological 
changes	before	becoming	invasive,	such	as	hyperplasia,	metaplasia,	
and	finally	dysplasia	and	carcinoma	in	situ.	Lung	cancer	is	classified	
by	the	site	of	origin,	and	method	of	diagnosis,	prognosis,	and	treat-
ment. The two main types of lung cancer are small cell lung can-
cer,	accounting	for	15%	of	all	cases,	and	non-small	cell	lung	cancer	
(NSCLC)	which	is	any	type	of	epithelial	lung	cancer,	and	accounts	for	
80%	to	85%	of	all	cases	(Figure	1).3 The three most common histo-
logical	forms	of	NSCLC	are	epidermoid	or	squamous	cell	carcinoma,	
large	 cell	 carcinoma,	 and	 adenoma;	 among	 them	 adenocarcinoma	
accounts	for	40%	of	all	lung	cancer	cases.4	Squamous	cell	carcinoma	
occurs	inside	the	airways,	adenocarcinoma	occurs	in	the	cells	lining	
the	alveoli	located	in	the	outer	part	of	the	lungs,	and	large	cell	carci-
noma	is	in	any	other	part	of	the	lung.	A	major	risk	factor	for	NCSLC	
is	smoking;5	other	risks	include	secondhand	smoke,	radiation	expo-
sure,	air	pollution,	family	history,	and	human	immunodeficiency	virus	
infection.	Lung	cancer	may	present	as	a	persistent	cough,	chest	pain,	
weight	loss,	malaise,	difficulty	breathing,	pleural	effusion,	pneumo-
nia,	chronic	obstructive	pulmonary	disease	or	pulmonary	fibrosis.6 
Diagnostic	procedures	 include	sputum	cytology,	 tissue	biopsy	and	
imaging	tests	such	as	bronchoscopy,	X-ray,	MRI,	positron	emission	
tomography,	or	computed	tomography	scan.7	Lung	cancer	is	staged	
based	on	the	size	of	the	primary	tumor,	the	involvement	of	the	lymph	
nodes,	and	the	presence	of	distant	metastasis.8
2  | MOLECULAR FEATURES OF NSCLC
Molecular	 features	 of	 NSCLC	 tumors	 may	 not	 only	 predict	 the	
prognosis and outcome the cancer but also serve as targets for 
therapies.	The	most	frequent	mutations	in	NSCLC	occur	in	the	TP53 
gene,	occurring	in	about	50%	of	NSCLC	cases	(Table	1).9	Mutations	
in	EGFR,	a	tyrosine	kinase	receptor,	account	for	10%-35%	of	cases	
and	can	cause	dysfunction	of	the	AKT	and	MAPK	signaling	which	
enhances cell survival and stimulates proliferation.10 The most 
common	 mutations	 of	 EGFR	 are	 in-frame	 deletions	 of	 exon	 19,	
and	the	second	most	common	EGFR	mutation	is	single	nucleotide	
substitutions	L858R	in	exon	21.11 The most common mutation de-
tected	after	treatment	with	EGFR	inhibitors	is	T790M	in	exon	20	
which can confer drug resistance.12	The	third	most	frequent	muta-
tions	occur	in	KRAS,	accounting	for	15%-25%	of	cases.13 Usually 
mutations	 in	 KRAS	 and	 EGFR	 are	 mutually	 exclusive	 and	 non-
overlapping.	Another	common	molecular	feature	of	NSCLC	is	the	
presence of ALK	 fusion	gene,	which	encodes	a	receptor	tyrosine	
kinase	not	normally	expressed	in	the	lung.13	At	least	nine	different	
variants	 of	 fusion	 of	 ALK	with	 an	 upstream	 partner	 EML4	 have	
been	 identified	 causing	 constitutive	 activation	 of	 the	 kinase.13 
The	HER2	protein,	a	HER	family	receptor	tyrosine	kinase,	is	over-
expressed	 in	20%	of	all	NSCLC	and	gene	amplification	occurs	 in	
2%.14,15 These mutations commonly lead to constitutive activation 
of	the	HER2	signaling	pathway.16	Mutations	in	the	main	catalytic	
subunit,	PIK3CA,	of	phosphatidylinositol	3-kinase	occur	 in	about	
F I G U R E  1  Lung	cancer	classifications	and	frequency	of	diagnosis.	There	are	two	main	types	of	lung	cancer:	small-cell	lung	cancer	and	
non-small	cell	lung	cancer.	Small-cell	carcinoma	occurs	in	the	outer	edges	of	the	lungs	and	accounts	for	about	15%	of	all	cases.	Non-small	
cell	lung	cancer	(NSCLC)	makes	up	85%	of	all	lung	cancer	cases,	and	can	be	further	classified	into	adenocarcinoma,	squamous	cell	carcinoma,	
and	large	cell	carcinoma.	Adenocarcinoma,	the	most	common	NSCLC	subtype,	occurs	in	the	cells	lining	the	alveoli,	squamous	cell	carcinoma	
is	generally	found	in	the	airways	or	bronchi,	and	large	cell	carcinoma	is	in	the	edges	of	the	lungs
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2%	of	NSCLC	cases.17	These	 tumors	can	activate	 the	protein	ki-
nase	B	signaling	pathway	without	growth	factors.	Protein	kinase	B	
is encoded by AKT1,	which	is	mutated	from	a	glutamate	to	a	lysine	
at	position	17	in	1%	of	NSCLC	cases	and	causes	PI3K-independent	
activation	of	protein	kinase	B.18,19	BRAF	is	a	member	of	the	RAF	
kinase	 family	 which	 confers	 signaling	 of	 the	MAPK	 family	 from	
the	RAS	GTPases	to	control	cell	proliferation.20	BRAF	mutations	
are	mostly	 found	 in	 adenocarcinomas	 and	 lead	 to	 higher	 kinase	
activity	and	constitutively	active	MAPK2	and	MAPK321.	MAPK2	
and	MAPK3	are	downstream	of	BRAF	and	three	mutations	in	the	
non-kinase	portion	of	these	proteins	have	been	found	in	cancer.22 
Amplification	 of	 the	 gene	MET,	which	 codes	 hepatocyte	 growth	
factor	receptor	(HGFR)	causes	resistance	to	EGFR	tyrosine	kinase	
inhibitors.23	 The	 molecular	 heterogeneity	 of	 NSCLC	 tumors	 in-
creases	the	complexity	of	treatment	for	NSCLC	patients.
3  | CURRENT TREATMENTS FOR NSCLC 
PATIENTS
Lung	 cancer	 that	 is	 diagnosed	 at	 the	 early	 stages	 is	 commonly	
treated	 with	 resection	 surgery	 or	 lobectomy,	 chemotherapy,	
and	 radiation.	 Surgery	may	 range	 from	 removing	 an	 entire	 lung	
to	 removing	 part	 of	 a	 lobe,	 depending	 on	 the	 size	 and	 location	
of	 the	 tumors.	 Radiation,	 alone	 or	 concurrent	 with	 surgery	 or	
chemotherapy	is	also	commonly	utilized.	External	beam	radiation	
therapy,	the	most	widely	used	form	of	radiation	for	NSCLC,	con-
sists	of	administering	1.5	to	2.5	Gray	to	the	lungs	usually	5	days	
a	week	for	5-7	weeks,	while	stereotactic	radiotherapy	consists	of	
a	 larger	 dose,	 around	 22	 Gray,	 in	 usually	 fewer	 than	 5	 doses.24 
Brachytherapy,	or	 internal	 radiation	 therapy,	 involves	 the	 insert-
ing a radioactive pellet in or near the tumor for a short amount of 
time	or	permanently.	The	radiation	stays	localized	and	gets	weaker	
over	time.	Radiofrequency	ablation	uses	radio	waves	emitted	from	
a probe guided by a computed tomography scan.
Molecular	medicine	or	pharmacotherapy	spans	from	chemotherapy	
to	targeted	therapy	and	the	most	recent	immunotherapy,	which	utilize	
small-molecule	 and	 protein	 or	 antibody	 drugs	 (Table	 2).	 Commonly	
used	 chemotherapies	 for	 the	 treatment	 of	NSCLC	 include	 cisplatin,	
carboplatin,	 docetaxel,	 paclitaxel,	 pemetrexed,	 and	 vinorelbine	 that	
usually	interfere	with	DNA	synthesis	or	replication	to	achieve	the	inhi-
bition	of	cancer	cell	proliferation	and	growth	(Table	2).	Nevertheless,	
chemotherapy may not be effective for all patients and many cancers 
will	 eventually	become	 resistant	 to	 the	drugs.	Furthermore,	 chemo-
therapy	kills	cancer	cells	 less	specifically	and	could	cause	some	side	
effects	like	pain,	nausea,	vomiting,	blood	disorders,	and	hair-loss.
Pharmacotherapy	for	NSCLC	has	been	benefited	greatly	by	the	de-
velopment	of	targeted	and	personalized	medications,	either	small	mol-
ecules	or	antibodies,	which	act	more	selectively	on	particular	molecular	
targets including transmembrane and cell surface proteins or receptors 
(eg,	EGFR,	PD-1,	PD-L1,	etc)	as	well	as	signal	proteins	(eg,	cytokines,	
VEGF)	and	cytoplasmic	kinases	(eg,	MEK)	(Table	2).	While	all	the	ther-
apies	listed	in	Table	2	are	approved	in	the	United	States,	many	are	also	
approved	in	Europe	and	elsewhere.	The	response	rate	for	most	of	the	
therapies is generally consistent across subtypes with higher rates for 
tumors with high mutational burden. The effectiveness of two anti-
body	drugs,	anti-VEGF	bevacizumab	and	anti-VEGFR	ramucirumab,	is	
attributable to the inhibition of angiogenesis.25	NSCLC	patients	with	
an	overexpression	of	EGFR	mRNA	or	increased	copy	number	have	a	
70%	or	higher	response	rate	to	small-molecule	EGFR	inhibitors	like	ge-
fitinib	or	EGFR	antibodies	like	necitumumab.26	Furthermore,	some	tar-
geted	therapies	are	approved	for	specific	subsets	of	NSCLC	patients.	
Osimertinib	is	used	to	treat	NSCLC	patients	with	T790M	mutations	of	
EGFR.	The	EML4‐ALK	tumors	are	mostly	responsive	to	small-molecule	
tyrosine	 inhibitors	of	ALK	 like	 crizotinib.	Dabrafenib	 and	 trametinib,	
which	target	BRAF	and	MEK1/2,	respectively,	are	prescribed	for	pa-
tients	with	BRAF	V600E	mutations.27	Immunotherapies	such	as	PD-1	
and	PD-L1	antibodies	(eg,	nivolumab	and	atezolizumab)	are	also	effec-
tive	for	the	treatment	of	some	NSCLC	patients	regardless	of	the	sub-
type.28	While	targeted	and	immunotherapies	are	generally	 less	toxic	
and	personalized	for	particular	patients,	some	patients	do	exhibit	pri-
mary	or	acquires	resistance	29,30 or show severe adverse effects such 
as diarrhea and pneumonitis.31-33	In	addition,	targeted	therapies	have	
the	greatest	 response	 rate	 for	patients	with	 the	 indicated	mutation,	
therefore,	due	to	the	high	heterogeneity	of	mutations	within	NSCLC,	
targeted	 therapies	may	not	work	 in	every	patient.	 Large	efforts	are	
underway	to	advance	the	understanding	of	NSCLC	biology	and	assess	
novel therapies.
4  | GENOME‐DERIVED MICRORNAS ARE 
DYSREGULATED IN NSCLC
As	 less	 than	5%	of	 the	 human	 genome	 is	 processed	 to	 functional	
proteins	in	cells,	the	majority	is	transcribed	into	enormous	numbers	
of	 functional	noncoding	RNAs.	Among	them,	microRNAs	 (miRNAs	
or	miRs)	are	a	superfamily	of	short	RNAs	that	act	on	corresponding	
transcripts	via	 complementary	binding	 to	achieve	mRNA	degrada-
tion or translation inhibition 34	(Figure	2).	The	biogenesis	of	miRNAs	
starts	with	 the	 transcription	 of	miRNA-coding	 genes	 into	 primary	
TA B L E  1   Common genetic alterations and their prevalence in 
NSCLC
Gene Alteration
Prevalence 
in NSCLC
TP53 Mutation 50%
EGFR Mutation 10%-35%
KRAS Mutation 15%-27%
ALK Fusion 5%-15%
HER2 Overexpression/	Gene	
amplification
20%/	2%
PIK3CA Mutation 2%-8%
AKT1 Mutation 1%
BRAF Mutation 5%
MET Mutation 5%
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TA B L E  2  List	of	drugs	approved	in	the	US	for	the	treatment	of	NSCLC	and	their	molecular	targets	or	mechanistic	actions
Treatment Classification Target or Action Approval Overall Response Rate
Bevacizumab antibody/protein VEGF Non-squamous	NSCLC 35%	with	carboplatin	and	
paclitaxel	150
Ramucirumab antibody/protein VEGFR Metastatic	non-squamous	
NSCLC
23%	with	docetaxel	151
Erlotinib small molecule EGFR EGFR	L858R	mutation,	
metastatic	NSCLC
74.4%	152
Necitumumab antibody/protein EGFR Metastatic	squamous	
NSCLC
48.1%	with	cisplatin	and	
gemcitabine 153
Gefitinib small molecule EGFR Advanced	or	metastatic	
NSCLC	with	L858R	EGFR	
mutations
76.9%	152
Afatinib small molecule EGFR Metastatic	squamous	
NSCLC	with	non-resistant	
EGFR	mutations
56%	154
Osimertinibe small molecule EGFR	T790M	mutations Advanced	or	metastatic	
NSCLC	with	T790M	EGFR	
mutations
77%	155
Crizotinib small molecule ALK/CD246,	ROS Advanced	or	metastatic	
ALK-positive	NSCLC
74%	156
Ceritinib small molecule ALK/CD246 Metastatic	ALK-positive	
NSCLC
58%	157
Brigatinib small molecule ALK/CD246 Metastatic	ALK-positive	
NSCLC
71%	158
Alectinib small molecule ALK/CD246,	RET Metastatic	ALK-positive	
NSCLC
82.9%	159
Dabrafenib small molecule B-Raf Metastatic	NSCLC	with	B-
Raf	V600E	mutation
67%	in	combination	with	
trametinib 160
Trametinib small molecule MEK Metastatic	NSCLC	with	B-
Raf	V600E	mutation
See	dabrafenib
Entrectinib small molecule ROS1/NTRK	fusion Metastatic,	ROS1/NTRK-
positive	NSCLC
78%	161
Nivolumab antibody/protein PD-1/CD279 Metastatic	squamous	
NSCLC
47%	in	patients	with	a	high	
tumor-mutation	burden	
162
Pembrolizumab antibody/protein PD-1/CD279 Advance	or	metastatic	squa-
mous	NSCLC
44.8%	163
Atezolizumab antibody/protein PD-L1/CD274/B7-H1 Metastatic	non-squamous	
NSCLC
63.5%	with	bevacizumab,	
carboplatin,	and	paclitaxel	
in	patients	with	no	EGFR	
or	ALK	alterations	164
Ipilimumab antibody/protein CTLA4/CD152 Metastatic	NSCLC 45.3%	with	nivolumab	165
Carboplatin & 
cisplatin
small molecule Inhibition	of	DNA	replication Advanced	or	metastatic	
NSCLC
62%	carboplatin	with	
paclitaxel	166
Irinotecan small molecule Topoisomerase I Advanced	NSCLC 43.7%	with	cisplatin	167
Etoposide small molecule Topoisomerase II Metastatic	NSCLC 21.9%	with	cisplatin	168
Docetaxel small molecule Microtubules;	inhibition	of	
mitosis
Advanced	NSCLC 9%	in	patients	previously	
treated with chemother-
apy 169
Paclitaxel small molecule Tubulin; inhibition of mitosis Advanced	or	metastatic	
NSCLC
See	carboplatin	&	cisplatin
Vinorelbine small molecule Tubulin; inhibition of mitosis Advanced	NSCLC 43%	with	cisplatin	170
(Continues)
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miRNA	 (pri-miRNA)	 transcripts.	 The	 pri-miRNA	 is	 thus	 processed	
by	 the	 Drosha-DGCR8	 complex	 within	 the	 nucleus	 to	 produce	 a	
precursor	miRNA	(pre-miRNA)	that	can	be	exported	into	the	cyto-
plasm	by	Ran-GTP-dependent	Exportin-5	(XPO5).	The	pre-miRNA	is	
cleaved	into	a	miRNA	duplex	by	the	RNase	Dicer	in	the	cytoplasm	35 
(Figure	2).	The	miRNA	duplex	is	then	unwound	to	offer	two	strands,	
among which the guide strand is preferably incorporated into the 
RNA-induced	silencing	complex	(RISC)	consisting	of	the	Argonaute	
family of proteins while the passenger strand is readily degraded.36,37 
The	RISC	proteins	stabilize	and	aid	the	mature	miRNA	in	binding	to	
the	3’-untranslated	region	 (3’UTR)	of	a	target	transcript	to	accom-
plish	the	regulation	of	target	gene	expression	(Figure	2).
Many	 miRNAs	 are	 involved	 in	 the	 control	 of	 target	 gene	 ex-
pression	 behind	 various	 cancer	 cellular	 processes	 (see	 the	 follow-
ing	 section),	 exhibiting	 tumor	 suppressive	 or	 promotive	 activities.	
Specifically,	a	miRNA	that	reduces	the	expression	of	tumor	suppres-
sors	acts	as	a	tumor	promotor,	and	a	miRNA	that	degrades	oncogene	
transcripts	 functions	 as	 a	 tumor	 suppressor.	 Interestingly,	 some	
miRNAs	 are	 dysregulated	 in	NSCLC	 (Table	 3)	 that	may	 be	 indica-
tive	 of	 disease	 status	 or	 therapeutic	 outcome.	With	 some	 excep-
tions,	 generally	 there	 is	 a	 decrease	 of	 tumor	 suppressive	miRNAs	
(eg,	miR-34a-5p	and	miR-124-3p)	and	increase	of	tumor	promotive	
miRNAs	(eg,	miR-21-5p	and	miR-183-5p)	in	many	human	cancers	in-
cluding	NSCLC	 (Table	3),	as	compared	to	normal	 tissues;	however,	
the magnitude of dysregulation varies by case. Dysregulation of 
miRNA	expression	may	be	caused	by	different	mechanisms	such	as	
chromosomal	deletion	or	methylation,	or	dysregulation	of	their	tran-
scription	 factors,	 enzymes,	 or	 binding	proteins	 involved	 in	miRNA	
biogenesis.	Dicer,	the	RNase	responsible	for	the	processing	of	pre-
miRNAs,	 is	 essential	 for	mouse	 development	 and	 stem	 cell	 main-
tenance.38 Dicer was reported to be downregulated in some lung 
cancer	patients,	leading	to	a	global	decrease	in	miRNAs	and	associ-
ated	with	poor	prognosis,39 and conditional deletion of Dicer led to 
increased lung tumorigenesis in mice.40	Actually,	the	role	of	Dicer	in	
cancer remains contradictive.41 It has been suggested that a partial 
loss	or	downregulation	of	Dicer	is	oncogenic,	while	a	complete	loss	
is	tumor	protective.	In	addition	to	Dicer,	the	expression	of	some	miR-
NAs	is	also	modulated	by	the	tumor	suppressive	transcription	factor	
p53.42	During	DNA	damage,	p53	associates	with	the	Drosha/DGCR8	
complex	and	facilitates	processing	of	pri-miRNA	to	pre-miRNA.	p53	
is	mutated	and	inactivated	in	many	cancers,	including	lung,43 reduc-
ing	the	total	levels	of	pre-miRNAs.	Taken	together,	a	global	decrease	
in	miRNA	levels,	by	either	decreased	Dicer	expression	or	loss	of	p53,	
might	 be	 involved	 in	 tumor	 initiation	 and	 progression.	 Ultimately,	
Treatment Classification Target or Action Approval Overall Response Rate
Vinblastine small molecule Microtubule;	inhibition	of	
mitosis
Advanced	NSCLC 41%	with	cisplatin	171
Pemetrexed small molecule Thymidylate	synthase,	dihy-
drofolate reductase
Advanced	NSCLC 9.1 in patients previously 
treated with chemother-
apy 172
Gemcitabine small molecule Inhibition	of	DNA	synthesis Advanced	or	metastatic	
NSCLC
40.6%	with	cisplatin	168
TA B L E  2   (Continued)
F I G U R E  2  MicroRNAs	are	derived	from	the	genome	to	control	target	gene	expression	through	their	actions	on	mRNAs.	Transcribed	
from	the	genomic	DNA	by	RNA	polymerase	as	primary	miRNA	(pri-miRNA)	and	subsequently	processed	by	the	Drosha/DGCR8	complex	to	
a	shorter	form	within	the	nucleus,	the	resultant	precursor	miRNA	(pre-miRNA)	is	transported	into	the	cytoplasm	by	Ran-GTP-dependent	
Exportin-5	(XPO5)	and	further	processed	by	Dicer	and	TRBP	to	miRNA	duplex.	Unwinding	of	the	duplex	offers	two	strands,	among	
which	the	passenger	strand	is	readily	degraded	while	the	mature	miRNA,	guided	by	argonaut-2	(AGO2),	acts	on	target	transcript	through	
complementary	binding	and	leads	to	mRNA	degradation	or	translational	inhibition
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restoration	 of	 tumor	 suppressive	miRNAs	 and	 inhibition	 of	 tumor	
promotive	miRNAs	represent	new	anti-cancer	strategies.
5  | MICRORNAS ARE INVOLVED IN THE 
CONTROL OF MULTIPLE NSCLC CELLULAR 
PROCESSES
5.1 | Epithelial to Mesenchymal Transition
The	epithelial	to	mesenchymal	transition	(EMT)	is	a	process	in	which	
an	 epithelial-like	 cell	 loses	 its	 attachment	 to	 the	 basal	membrane	
and	assumes	mesenchymal	characteristics	 like	greater	motility	and	
invasiveness.	EMT	allows	for	cancer	cells	to	metastasize	by	migrat-
ing from the primary tumor through the blood stream and invading 
other	organs.	Comprehensive	reviews	of	the	process	of	EMT	have	
recently been published.44	Some	miRNAs	can	affect	cells’	ability	or	
likelihood	to	undergo	EMT	by	regulating	the	expression	of	EMT-re-
lated	genes.	One	important	EMT	signaling	cascade	involves	TGFβ,	is	a	
signaling	cytokine,	that	binds	to	its	receptor,	TGFβR1/2 to transduce 
a	signal	through	RAS,	PI3K,	RhoA/ROCK,	or	Smad2/3	and	activate	
transcription	factors,	like	ZEB1/2,	Twist	and	Snail.	This	ultimately	re-
sults	in	the	loss	of	epithelial	attachment	proteins,	such	as	E-cadherin,	
and	gain	of	intermediate	filament	or	cell-cell	adhesion	proteins,	such	
as	 vimentin	 and	 N-cadherin.45	 The	 EMT	 phenotype	 is	 reduced	 in	
NSCLC	by	the	action	of	miR-17-5p,	20a-5p,	and	20b-5p	that	directly	
target	TGFβR2,46	miR-148a-3p	and	miR-101-3p	that	target	ROCK1	
and	ROCK2	respectively,47,48	and	miR-132-3p,	miR-638-5p,	and	miR-
338-5p	which	target	transcription	factors	ZEB2,	SOX2,	and	SOX4,	
respectively 49-51	(Figure	3).	Both	miR-149-5p	and	miR-509-3p	target	
the	 transcription	 factor	FOXM1	to	 reduce	 invasion	 in	H1299	cells	
as	determined	by	Matrigel	invasion	assay.52	In	addition,	miR-186-5p	
targets	 CDC42	 leading	 to	 the	 inhibition	 of	 migration	 and	 related	
EMT	processes.53	Likewise,	dysregulation	of	these	miRNAs,	as	evi-
dent	in	NSCLC,	leads	to	greater	EMT	and	a	more	invasive,	migratory,	
and potentially metastatic phenotype.
5.2 | Signal transduction in lung cancer survival and 
proliferation
Oncogenesis	 is	 driven	 by	 an	 over-expression	 or	 activation	 of	
growth	 signaling,	 such	 as	 growth	 factors,	 receptors,	 or	 down-
stream	 signaling	molecules.	 Growth	 factor	 ligands	 bind	 to	 their	
corresponding receptors to relay a signal and induce prolif-
eration.	 Cancer	 cells	 can	 hijack	 signaling	 by	 over-expressing	 or	
mutating growth factor receptors to increase proliferative sig-
nals	 and	miRNAs	 target	 certain	 receptor	 to	modulate	 signaling.	
miRNA Expression Direct Targets Verified References
miR-124-3p Decreased STAT-3,	MYO10,	SMAD4 [173-176]
miR-126-3p Decreased PIK3R2,	VEGF-A,	Crk [77,120,177-179]
miR-143-3p Decreased KRAS,	NRAS,	BCL2,	HK2,	
PKCε,	Limk1,	ATG2B
[112,180-186]
miR-34a-5p Decreased TGFβR2,	Cyclin	E1,	PEBP4,	
Notch-1,	Axl
[187-192]
let-7c-5p Decreased N/K-RAS,	ABCC2,	Bcl-XL,	
ITGB3,	MAP4K3,	HOXA1
[122,193-196]
miR-101-3p Decreased ZEB1,	ROCK2,	MALAT-1,	
EZH2
[48,180,197-199]
miR-100-5p Decreased FGFR3,	PLK1 [67,180,200,201]
miR-181a-5p Decreased BCL2,	KRAS,	VCAM-1,	
CDK1
[99,180,202-204]
miR-145-5p Decreased c-Myc,	SMAD3,	AEG/
MTDH,	OCT4,	SOX2,	
Fascin1
[138,202,205-207]
miR-486-5p Decreased PIM-1,	ARHGAP5,	IGF1,	
IGFR,	p85α,	CDK4
[62,63,208-210]
miR-451a-5p Decreased PSMB8,	RAB14 [175,180,211]
miR-21-5p Increased PTEN [180,212]
miR-210-3p Increased E2F3,	NDUFA4,	SDHD [79,213]
miR-205-5p Increased PTEN,	PHLPP2,	ITGα5 [131,214-216]
miR-31-5p Increased ABCB9,	hMLH1 [121,180,217]
miR-200b-5p Increased FOXF2,	IL-8,	CXCL1,	
FSCN1
[129,218-220]
miR-182-5p Increased PDCD4,	RGS17 [213,221-223]
miR-183-5p Increased FOXO1,	VIL2 [134,213,224]
TA B L E  3  List	of	miRNAs	most	
commonly	dysregulated	in	NSCLC	and	
some of their corresponding targets 
validated	by	biological	experiments
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miR-7-5p,54	 miR-133b-3p,55	 miR-134-5p,56	 and	 miR-200a-3p	 57 
target	epidermal	growth	 factor	 (EGFR)	 (Figure	3),	which	 is	 com-
monly	 overexpressed	 in	 NSCLC	 (Table	 1),	 to	 alter	 downstream	
signaling	molecules	 such	 as	 AKT	 and	 ERK1/2	 and	 decrease	 the	
growth	phenotype.	In	addition,	miR-139-5p,58	miR-30a-5p,59	miR-
140-3p,60	miR-320a-3p	61	and	miR-195-5p	62	all	target	insulin-like	
growth	factor	1	receptor	(IGF1R),	while	miR-486-5p	directly	tar-
gets	both	IGF1R	and	its	ligand	insulin-like	growth	factor	1	(IGF1)	
63	and	miR-135a-5p	targets	only	IGF1.64	miRNA	inhibition	of	the	
IGF	pathway	results	in	a	lower	proliferation	as	assayed	by	CCK-8	
kit	among	others.60	miR-152-3p	 targets	 fibroblast	growth	 factor	
2	 (FGF2)	 65	 and	miR-99b-5p	 66	 and	miR-100-5p	 67 target fibro-
blast	growth	factor	receptor	3	(FGFR3).	MET	is	a	receptor	for	the	
hepatocyte	growth	factor	 (HGF)	and	 is	 targeted	by	a	number	of	
miRNAs	 including	miR-130a-3p,68	miR-449a-5p	69	miR-34a-5p,70 
miR-200a-3p,57	 miR-206-3p,71	 miR-31-5p,72	 miR-139-5p,73	 miR-
329-3p,74	 miR-27b-3p	 75 to decrease growth and proliferation. 
EGF,	 IGF,	FGF,	and	HGF	signaling	results	 in	activation	of	RAS	or	
PI3K	pathways	and	downstream	growth	signaling.	A	decrease	 in	
the	miRNAs	that	target	growth	factors	and	their	receptors,	as	well	
as	downstream	targets,	as	evident	in	NSCLC,	results	in	an	increase	
in growth signal transduction and an increase in cancer cell prolif-
eration and growth.
5.3 | Angiogenesis
Angiogenesis	is	the	process	of	building	new	blood	vessels	for	nutri-
ents	and	gas	exchange	which	is	essential	for	cancer	cells	to	survive	
and	proliferate.	Dysregulation	of	miRNAs	in	cancer	cells	can	lead	to	
increased	angiogenesis	through	multiple	pathways,	including	vascu-
lar	endothelial	growth	factor	(VEGF)	or	placenta	growth	factor	(PIGF)	
binding	 to	 VEGF	 receptor	 (VEGFR)	 or	 neuropilin	 (NRP).76 During 
normal	conditions,	 tumor	suppressor	von	Hippel	Lindau	 (vHL)	me-
diates	the	degradation	of	hypoxia-inducible-factor-1	(HIF1)	through	
the	 ubiquitin-proteasome	pathway.	By	 contrast,	HIF-1α associates 
with	HIF1β	 during	 hypoxia	 and	 thus	 increases	VEGF	 transcription	
by binding to the promoter.76	 miRNAs	 regulate	 many	 important	
factors	 of	 angiogenesis	 (Figure	 3).	 For	 example,	 miR-126-3p	 and	
miR-128-3p,	 both	 of	 which	 are	 commonly	 decreased	 in	 NSCLC,	
directly	 target	 VEGF-A	 and	 VEGF-C,	 respectively,	 to	 decrease	
F I G U R E  3  MicroRNAs	modulate	many	cancer	cellular	processes	important	in	tumor	initiation,	progression,	and	metastasis.	(A)	The	
epithelial	to	mesenchymal	transition	(EMT)	is	driven	in	part	by	transforming	Growth	Factor	β	(TGFβ)	binding	to	the	TGFβ	Receptor	(TGFβR)	
and	signaling	to	RAC	and	activating	RhoA	and	ROCK.	SMAD2/3	signaling	activates	transcription	factors	ZEB,	FOXM,	and	SOX	to	turn	on	
transcription	of	other	genes	necessary	for	EMT.	Some	miRNAs	that	target	TGFβR,	CDC42,	ROCK,	or	the	downstream	transcription	factors	
are	dysregulated	in	NSCLC,	which	can	increase	EMT	signaling	and	therefore	enhance	cancer	cell	invasion	and	metastasis.	(B)	Growth	factors	
(GF),	such	as	epidermal	growth	factor	(EGF),	bind	to	corresponding	growth	factor	receptors,	such	as	EGF	receptor	(EGFR),	to	activate	RAS	or	
PI3K.	This	leads	to	a	series	of	signal	transductions	that	eventually	enhance	cancer	cell	proliferation	and	growth.	Inhibition	of	growth	factors	
and	their	receptors	by	miRNAs	may	inhibit	tumor	progression.	(C)	One	mechanism	behind	angiogenesis	involves	vascular	endothelial	growth	
factor	(VEGF)	binding	to	VEGF	Receptor	(VEGFR)	and	activating	hypoxia-inducible	factor-1α	(HIF1α).	Those	miRNAs	that	target	VEGF	or	
HIF1α may reduce angiogenesis essential for tumor progression
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angiogenesis	and	blood	vessel	formation,	as	measured	by	tube	for-
mation assay.77,78	miR-210-3p	is	overexpressed	in	late-stage	NSCLC	
and	protects	against	hypoxia	induced	apoptosis	by	indirectly	stabi-
lizing	HIF1α to promote angiogenesis and increase glycolysis.79	miR-
21-5p	directly	targets	PTEN	and	activates	AKT	and	ERK1/2	which	
leads	to	higher	levels	of	HIF1α	and	VEGF	expression.80	miR-378-5p	
is	 over-expressed	 in	 NSCLC	 tumors	 in	 patients	 with	 brain	metas-
tasis	 and	 leads	 to	 increased	VEGF	 expression	 and	 angiogenesis.81 
miR-206-3p	directly	 suppresses	 the	expression	of	protein	14-3-3ζ 
which	 consequently	 decreases	 VEGF,	 HIF1α,	 and	 phosphorylated	
STAT3	and	results	in	a	lower	degree	of	angiogenesis	as	assayed	by	
HUVECs	recruitment	as	well	as	 inhibition	of	 intratumoral	capillary	
tube formation in vivo.82	In	one	study,	coculture	of	NSCLC	cell	lines	
with	vascular	endothelial	cells	leads	to	higher	levels	of	miR-494-3p	
in	 the	 vascular	 endothelial	 cells,	 in	 addition,	 a	miR-494	 antagomir	
decreases	 tumor	 vascularization,	 suggesting	 that	 miRNAs	may	 be	
transferred to vascular endothelial cells to control angiogenesis.83 
Such	miRNAs	are	important	in	the	control	and	development	of	vas-
cularization	which	is	critical	for	tumorigenesis	and	metastasis.
5.4 | Cell Cycle
The cell cycle is altered among almost all cancer cells to allow for 
uncontrolled	growth.	Cyclins	and	cyclin-dependent	kinases	(CDKs)	
are partly responsible for entry into the different cell cycle stages. 
G1	begins	with	cyclins	D1,	D2,	and	D3	associating	with	CDK4	and	
6	 84	 to	phosphorylate	Rb	 and	 repress	 the	E2F	 transcription	 fac-
tor.85	G1/S	transition	is	characterized	by	cyclin	E	complexing	with	
CDK2	86	and	cyclin	A/CDK2	complex	during	S	phase.87	Cyclin	A	
complexes	with	CDK1	to	transition	to	M	phase,	then	cyclin	B	and	
CDK1	are	complexed	during	M	phase.88	Such	proteins	regulating	
G1	and	S	phases	of	many	types	of	cancers,	 including	NSCLC,	are	
dysregulated,	 and	 some	 are	 direct	 targets	 of	 particular	miRNAs	
(Figure	4	and	Table	3).	Tumor	suppressive	miR-34a-5p	directly	tar-
gets	CCND1	and	CDK6,	 leading	 to	 the	arrest	of	 the	cell	cycle	 in	
G1 phase.
89	 Furthermore,	miR-15a-5p	 and	miR-16-5p,	 down-reg-
ulated	 in	 NSCLC,	 directly	 targets	 CCND1,	 CCND2,	 and	 CCNE1,	
and	 arrests	 the	 cell	 cycle	 in	G1	 to	G0	 in	 an	 Rb-dependent	man-
ner.90	Combination	of	miR-34a-5p	and	miR-15a/16	produces	syn-
ergism	in	G1	cell	cycle	arrest	 in	an	Rb-dependent	manner	due	to	
an	increase	in	miRNAs	targeting	more	cell	cycle	related	mRNAs.91 
In	 addition,	 miR-30d-5p	 targets	 CCNE2,92	 miR-186-5p	 targets	
CCND1,	CDK2,	and	CDK6,93	and	miR-129-5p	targets	CDK6	94 to 
arrest	the	cells	 in	G1.	Generally,	cell	cycle-regulating	miRNAs	ex-
hibit tumor suppressive actions by targeting cell cycle promotive 
genes to induce a cancer cell cycle arrest.
5.5 | Evading Apoptosis
Cell	 death	mechanisms,	 including	 apoptosis	 or	 necrosis,	 are	 im-
portant	 for	 cells	 to	 maintain	 homeostasis,	 and	 dysregulation	 of	
these	pathways	leads	to	an	alteration	of	cell	proliferation,	includ-
ing	NSCLC	cells.	Some	miRNAs	regulate	certain	proteins	involved	
in	 cell	 death	 (Figure	 5),	 and	 dysregulation	 of	 such	miRNAs	may	
make	the	cells	evade	death	signals	and	continue	to	proliferate.	In	
brief,	apoptosis	occurs	when	a	death	ligand,	such	as	tumor	necro-
sis	 factor	 (TNF)-related	 apoptosis-inducing	 ligand	 (TRAIL),	 binds	
to	a	death	receptor,	 including	TNF	receptors	1	and	2	(TNFR1/2),	
causing	 receptor	multimerization	and	activation	of	 the	death	 in-
duced	 signaling	 complex	 (DISC).95 This can result in direct acti-
vation	 of	 caspase-8	 mediated	 cleavage	 of	 effector	 caspases,	
like	 caspase-3,96	 or	 caspase-8	 cleavage	 of	 Bid	 which	 releases	
mitochondrial	 cytochrome	 c	 to	 associate	with	 Bax	 and	 Bak	 and	
forms the apoptosome and cleaves effector caspases.97	 BCL2,	
an	anti-apoptotic	protein	 that	mainly	 functions	 to	 inhibit	 release	
of	 cytochrome	 c	 from	 the	 mitochondria,98	 is	 targeted	 by	 miR-
181-5p,99	miR-7-5p,100	miR-503-5p,101	miR-200bc/429	 cluster,102 
and	miR-497-5p	103	(Figure	5).	In	addition,	BCL2L2	and	BCL6,	also	
anti-apoptotic	 proteins,	 are	directly	 targeted	by	miR-15a-5p	 and	
miR-187-3p,	 respectively,	 to	 enhance	 apoptosis.104,105	 TRAIL	 ex-
pression	 induces	 apoptosis;	 however,	 NSCLC	 can	 confer	 resist-
ance	 to	 TRAIL-mediated	 apoptosis	 through	 many	 mechanisms	
including	 loss	of	PTEN	and	constitutive	activation	of	AKT	 106 or 
increased	matrix	metalloproteases.107	Therefore,	over-expression	
F I G U R E  4  MicroRNAs	directly	target	
core	cell	cycle	regulators.	Some	miRNAs,	
such	as	miR-34a-5p,	miR-186,	and	miR-15,	
which	regulate	the	expression	of	cell	cycle	
regulators,	are	downregulated	in	NSCLC.	
This causes dysregulation of the cell 
cycle and ultimately increases cancer cell 
proliferation. Restoration of such tumor 
suppressive	miRNAs	may	lead	to	cell	cycle	
arrest to achieve anticancer effects
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of	 miR-148a-3p	 can	 sensitize	 NSCLC	 to	 TRAIL	 by	 targeting	
MMP15.108	miR-221-3p	and	miR-222-3p	can	confer	TRAIL	resist-
ance	by	targeting	tumor	suppressors	PTEN	and	tissue	inhibitor	of	
metalloproteases	 3	 (TIMP3),109	 while	 miR-130a-3p	 can	 reverse	
this	effect	by	targeting	miR-221-3p	and	miR-222-3p.68	miR-21-5p	
also	targets	PTEN	and	results	in	the	inhibition	of	apoptosis,	which	
can	be	reversed	by	the	transfection	of	anti-miR-21-5p.110
5.6 | Metabolism
Some	 miRNAs	 can	 alter	 the	 metabolic	 potential	 of	 cancer	 cells.	 A	
higher metabolic rate may enhance the tumorigenesis and growth of 
NSCLC	 cells.	 miR-155-5p	 promotes	 aerobic	 glycolysis	 by	 indirectly	
upregulating	HK2,	as	determined	by	a	hexokinase	colorimetric	assay	
as	well	 as	glucose	and	L-lactate	 test	kits.111 The increase in glycoly-
sis	leads	to	greater	degree	of	cell	viability.	miR-143-3p	directly	targets	
HK2,	the	first	rate-limiting	enzyme	in	glycolysis,	to	decrease	glycolysis	
and proliferation as well as tumorigenesis in vivo.112	miR-124-3p	over-
expression	 decreases	 glucose	 consumption,	 lactate	 production,	 and	
ATP	content	by	decreasing	HK2	and	glucose	transporter	1	 (GLUT1),	
leading	to	a	lower	extent	of	cell	proliferation.113	miR-449-5p	directly	
targets	lactate	dehydrogenase	A	(LDHA)	and	suppresses	glycolysis.114 
miR-182-5p	and	miR-31-5p	target	HIF1AN	and	FIH,	respectively,	both	
of	which	are	HIF-1α inhibitors and lead to enhanced glycolysis.115,116 
miR-210-3p	directly	targets	two	genes	important	in	the	electron	trans-
port	chain,	NADH	dehydrogenase	(ubiquinone)	1	alpha	subcomplex	4	
(NDUFA4),	and	succinate	dehydrogenase	complex	subunit	D	(SDHD),	
which	leads	to	alteration	of	the	physical	structure	of	the	mitochondria,	
visualized	by	electron	microscopy	as	well	as	alterations	of	 the	mito-
chondrial membrane potential that are phenotypic of mitochondria 
dysfunction.79	miR-145-5p	and	miR-138-5p	directly	 target	phospho-
inositide-dependent	protein	kinase-1	(PDK1),	an	important	enzyme	in	
glucose and fatty acid metabolism.115,117 Dysregulation or loss of those 
miRNAs	that	inhibit	the	metabolic	potential	of	NSCLC	cells	may	alter	
tumor progression.
6  | MICRORNAS AFFECT THE SENSITIVITY 
OF NSCLC CELLS TO CURRENT THERAPIES
Dysregulation	of	miRNAs	can	confer	the	resistance	to	current	thera-
pies	 including	 chemotherapy	 and	 radiation	 therapy.	 For	 instance,	
upregulation	of	miR-21-5p	leads	to	a	reduction	of	apoptosis	and	de-
crease	of	sensitivity	to	two	chemotherapeutics,	docetaxel	and	cispl-
atin.110	 Induced	by	 radiation,	miR-155-5p	does	 confer	 resistance	 to	
radiation	 therapy	 by	 indirectly	 increasing	 HK2	 to	 promote	 aerobic	
glycolysis.111	Furthermore,	chronic	treatment	with	EGFR	inhibitor	ge-
fitinib	 reduces	 the	 expression	of	miR-155-5p	 and	miR-200c-3p	 and	
may decrease the sensitivity to gefitinib.118	 Therefore,	miRNA	pro-
files from tissue or body fluids may also be used as predictive bio-
markers	for	the	sensitivity	of	NSCLC	tumors	to	certain	therapies	and	
to	determine	optimal	 therapies	 for	 the	 treatment	of	NSCLC.	As	 an	
example,	 miR-143-3p	 is	 downregulated	 in	 NSCLC	 and	 suppresses	
NSCLC	cell	proliferation,	migration,	and	invasion	by	regulating	EGFR	
expression.119	NSCLC	patients	showing	lower	miR-143-3p	levels	and	
higher	EGFR	levels	may	benefit	from	anti-EGFR	therapy	like	gefitinib.	
PI3K	or	VEGF	inhibitors	may	be	beneficial	for	patients	with	decreased	
expression	of	miR-126-3p	because	dysregulation	of	miR-126-3p	may	
lead	to	an	increase	in	PI3K	and	VEGF-A.77,120	In	addition,	miRNAs	can	
play	an	important	role	in	drug	uptake	and	efflux	via	direct	targeting	of	
drug	transporters.	For	example,	miR-31-5p	is	upregulated	in	cisplatin	
resistant	cell	lines	and	directly	regulates	the	expression	of	ABCB9,	a	
drug	transporter,	 to	confers	cisplatin	resistance.121	Let-7c-5p	modu-
lates	 the	expression	of	ABCC2	 transporter	 to	 sensitize	cisplatin	 re-
sistant cells.122	ABCC4	involved	in	the	transport	of	many	anti-cancer	
drugs	such	as	methotrexate	and	topotecan	and	is	directly	targeted	by	
miR-124-3p	and	miR-506-3p.123	Excellent	reviews	on	the	potential	of	
miRNAs	as	biomarkers	in	lung	cancer	have	been	recently	published.124 
Understanding	miRNA-controlled	 regulation	may	 not	 only	 improve	
the understanding of multidrug resistance mechanisms but also offer 
clues to the development of new therapeutic strategies.125,126
7  | MICRORNAS IMPACT THE 
TUMORIGENESIS OF NSCLC CELLS
To	determine	the	effect	of	a	miRNA	on	tumorigenesis,	investiga-
tors	transiently	or	stably	express	the	target	miRNA	in	a	cell	line	
for implantation in vivo. While this does not necessarily model 
therapeutic	potential	 of	miRNAs,	 it	 does	provide	 important	 in-
formation	beyond	cell-based	findings	regarding	the	 importance	
of	miRNAs	 in	 the	 control	 of	 tumor	 initiation	 and	 development	
or	 tumorigenesis	 (Table	4).	For	example,	 subcutaneously	or	 tail	
vein	 injected	 A549	 cells	 expressing	 miR-124-3p,	 miR-126-3p,	
miR-143-3p,	miR-34a-5p,	 Let-7b-5p,	 or	miR-182-5p	 showed	 re-
duced tumor growth and in some cases reduce lung metastasis 
F I G U R E  5  miRNAs	affect	the	ability	to	evade	of	apoptosis.	
BCL6,	BCL2L2,	and	BCL2	are	anti-apoptotic	as	they	inhibit	
cytochrome c release from the mitochondria. Dysregulation or 
malfunction	of	miRNAs	in	NSCLC	that	inhibit	the	anti-apoptotic	
cascade may reduce apoptotic capacity and enhance cancer 
progression.	Therefore,	restoration	of	such	miRNA	expression	or	
function represents a novel therapeutic strategy
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as	 compared	 to	 control	 cells.	 Lewis	 lung	 carcinoma	 cells	 tran-
siently	transfected	with	miR-101-3p	displayed	a	smaller	increase	
of tumor volume over time when subcutaneously injected into 
the	flank	of	mice,	as	well	as	a	reduction	of	metastasis	to	the	lung	
when intraperitoneally injected.127	 Cells	 overexpressing	 miR-
145-5p	or	miR-486-5p	subcutaneously	implanted	or	tail	vein	in-
jected in mice displayed a slower rate of tumor growth.62,128	Lung	
cancer	cells	344SQ	transfected	with	miR-200a-3p	or	miR-200b-
5p or both showed smaller tumor volume with transfection of 
both	miRNAs	having	the	greatest	 impact.129	By	contrast,	trans-
genic	 KRAS	mutant	mice	with	 conditionally	 global	 overexpres-
sion	of	miR-21-5p	showed	much	greater	tumor	burden	as	well	as	
lower	survival	rate,	as	compared	to	KRAS	mutant	mice	without	
miR-21-5p	overexpression.130	After	subcutaneous	 implantation,	
H460	 cells	 overexpressing	 miR-205-5p	 grew	 faster	 and	 led	 to	
greater	tumor	volume	and	vascularization,	as	compared	to	con-
trol cells.131	 Compared	 to	 corresponding	 controls,	 overexpres-
sion	of	miR-31-5p	in	three	different	lung	cancer	cell	lines,	H1993,	
H1437,	and	H460,	led	to	an	increase	in	subcutaneous	tumor	vol-
ume.132 The same study also demonstrated that transgenic mice 
with	 a	 doxycycline-inducible	miR-31-5p	 expression	 in	 the	 lung	
exhibited	greater	levels	of	hyperplasia	and	adenomas.132 In con-
clusion,	ectopic	or	overexpression	of	certain	functional	miRNAs	
can	 largely	 influence	 the	 tumorigenesis	 of	 NSCLC	 cells,	 which	
may	 provide	 insights	 into	 development	 of	 new	 miRNA-based	
therapies.
8  | THERAPEUTIC POTENTIAL OF 
MICRORNAS DEMONSTRATED IN NSCLC 
ANIMAL MODELS IN VIVO
Two	 miRNA-based	 therapeutic	 strategies	 have	 been	 established,	
aiming	to	restore	tumor	suppressive	miRNAs	and	inhibit	tumor	pro-
motive	miRNAs,	 respectively.	Many	 studies	 were	 thus	 conducted	
to	define	the	effectiveness	of	specific	miRNA	therapeutics	for	the	
treatment	of	NSCLC	in	animal	models	in	vivo	(Table	5).	AntagomiRs	
were	 employed	 for	 the	 inhibition	 of	 tumor	 promotive	 miR-21-5p,	
miR-183-5p,	 and	 miR-206-3p	 and	 shown	 to	 inhibit	 subcutaneous	
A549	tumors.82,133,134	Whereas,	tumor	suppressive	miRNAs	let-7b-
5p	or	miR-34a-5p	reduced	KRAS-activated	tumor	burden	in	vivo.135 
Let-7c-5p	and	let-7a-5p	were	both	shown	to	decrease	the	progres-
sion	of	NSCLC	 in	vivo.136	Synthetic	miR-34a-5p	 injected	either	 in-
tratumorally or through the tail vein was effective in inhibiting the 
growth	of	 subcutaneous	xenograft	NSCLC,137 and it did not show 
major	 impact	on	the	cytokine	profiles	or	 liver	or	kidney	functions.	
A	 specific	 type	 of	 chemical	 modification	 of	 miR-145-5p,	 namely	
locked	nucleic	acid,	delivered	with	a	polyurethane-short	branched-
polyethylenimine,	 led	to	significant	inhibition	of	tumor	growth	and	
the effects were enhanced by radiation and cisplatin therapy.138 
Orthotopic	 NSCLC	 tumor	 growth,	 metastasis,	 and	 vascularization	
were	 decreased	 in	 mice	 treated	 with	 miR-200a/b.129	 miR-29b-3p	
decreased cell proliferation and increased apoptosis in subcutane-
ous	NSCLC	tumors.139	Combination	treatment	with	miR-34a-5p	and	
TA B L E  4  Some	miRNAs	shown	to	affect	tumorogenesis	of	NSCLC	cells	in	animal	models
miRNA Cell line Mouse strain Finding Reference
miR-124-3p A549 nude	BALB/c Reduced lung metastasis from tail vein 
injected cells
[176]
miR-126-3p A549 nude	BALB/c Reduced tumor wieght [77]
miR-143-3p A549 nude	BALB/c Reduced tumor wieght [225]
miR-34a-5p A549 nude	BALB/c Reduced	tumor	wieght,	and	lung	tumor	
metastasis
[226]
let-7b-5p A549,	H460 nod/scid Reduce tumor growth [227]
miR-101-3p LLC C57BL/6 Reduced	tumor	wieght,	metastasis	from	IP	
injected cells
[127]
miR-100-5p SPC-A1/DTX nude Reduced tumor volume in response to 
docetaxel
[201]
miR-145-5p A549	CIC nude Reduced tumor volume [128]
miR-486-5p H460-luc2 athymic	Swiss Reduced lung metastasis from tail vein 
injected cells
[62]
miR-451-5p A549 nude	BALB/c Reduced tumor volume in respose to 
cisplatin
[228]
miR-21-5p CAG-miR-21;K-rasLA2 Reduced tumor burden and increased 
survival
[130]
miR-205-5p H460 BALB/c Reduced tumor volume [131]
miR-31-5p H1993/	H1437/H460 nude Reduced tumor volume [132]
miR-200a/b 344SQ nude Reduced tumor volume [129]
miR-182-5p A549 nude Reduced tumor volume and weight and 
increased survival
[229]
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let-7c-5pwas	 effective	 in	 improving	 overall	 survival	 and	 reducing	
tumor	burden	in	KRAS	mutant	mice.140	Nevertheless,	the	majority	of	
miRNAs	used	for	in	vivo	therapies	are	made	by	chemical	synthesis	or	
in	vitro	transcription,	or	achieved	through	viral	vectors	or	plasmids,	
where	RNAs	or	mimics	are	often	delivered	with	lipids	or	polymers.	
Very	recently,	a	novel	RNA	bioengineering	technology	has	been	es-
tablished	for	the	production	of	new	miRNA	reagents	for	the	assess-
ment	of	miRNA	therapies.141-145	Biologic	or	recombinant	miR-34a-5p	
or	miR-124-3p	molecules	 produced	 in	 bacteria	 and	delivered	with	
in	 vivo-jetPEI	 into	 tumor-bearing	 mouse	 models	 decreased	 the	
growth	of	both	subcutaneous	and	metastatic	NSCLC	tumors,	with	
minimal	 influence	on	 blood	 chemistry	 or	 cytokine	 profiles,	 in	 two	
different studies.144,145	A	variety	of	different	delivery	methods	have	
been	tested	in	vivo	to	deliver	the	above-mentioned	miRNAs.	Many	
miRNAs	 were	 formulated	 with	 lipid-based	 technologies,	 such	 as	
liposomes,	 lipoplex,	 siPORTamine,	 and	MaxSuppressor,	which	 sur-
round	the	RNA	and	protect	it	from	degradation.136,137,139,140,146	Viral	
vectors,	such	as	lentivirus	or	adenovirus,	as	well	is	positively	charged	
polyethylenimine,	 which	 associates	 with	 the	 negatively	 charged	
RNA,	were	also	used.134,136,138,144,145	 In	most	 cases,	miRNA	 thera-
peutics	 were	 administered	 through	 the	 tail	 vein	 or	 intra-tumoral	
injection.	These	in	vivo	findings	demonstrate	the	promise	of	miRNA-
based	therapies	for	the	treatment	of	NSCLC.
One	 tumor	 suppressive	 miRNA,	 namely	 MRX34	 or	 liposomal	
miR-34a	mimic,	was	also	moved	into	first-in-human	Phase	I	clinical	tri-
als.147	It	was	evaluated	as	dose-escalating	intravenous	infusions	under	
a	regimen	of	twice	a	week	in	three-week	cycles.	This	study	consisted	
of	47	patients	with	advanced	solid	tumors,	including	one	patient	with	
NSCLC	who	had	stable	disease	for	8	cycles	of	treatment.	While	effi-
cacy	of	MRX34	was	obvious	among	some	patients,	96%	of	all	patients	
TA B L E  5  Some	miRNA-based	therapies	for	the	treatment	of	NSCLC	assessed	in	animal	models	in	vivo
miR Mouse model Delivery Findings Reference
let-7b-5p	and	miR-34a-
5p	(synthetic)
Cre-Kras	mutant Neutral	lipid	emulsion	
(NLE)
Lower	tumor	burden,	increased	apoptosis,	
decreased proliferation
[135]
let-7b-5p	(synthetic) Subcutaneous	H460	
cell line
siPORTamine	(lipid	based) Decreased proliferation [136]
let-7a-5p
(lenti-let-7)
Cre-Kras	mutant Lentiviral Decreased proliferation [136]
miR-34a-5p	(synthetic) Subcutaneous
H460
MaxSupressor	in	vivo	
RNALancerII	(lipid	based)
Decreased	proliferation,	increased	apop-
tosis,	minimal	change	in	blood	chemistry	
or	cytokine	profile
[137]
miR-145-5p	(synthetic;	
LNA)
Subcutaneous,	intra-
bronchial or intrave-
nous patient derived 
primary lung adenocar-
cinoma CD133+
Cationic	polyurethane-
short branched polyethyl-
enimine	(PU-PEI)
miR-145-5p	alone	showed	moderate	
tumor	inhibition,	increased	tumor	inhibi-
tion and survival in combination with 
radiation and cisplatin
[138]
miR-200a/b	(synthetic) intrapulmonary	344SQ	
(murine)	cell	line
1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine 
(DOPC)	nanoliposomes
Reduced	proliferation,	metastasis,	and	
tumor	vasculature	permeabilization
[129]
miR-29b-3p	(synthetic) Subcutaneous	A549	
cell line
Lipoplex Suppressed	target	expression,	reduced	
proliferation,	increased	apoptosis
[139]
miR-34a-5p	&	miR-
124-3p	(biologic	RNA)
Intravenous	A549	cell	
line,	(metastatic)
In	vivo-jetPEI Decreased	lung	lesions,	minimal	change	
on	blood	chemistry	or	cytokine	release
[144]
miR-34a-5p	(biologic	
RNA)
Subcutaneous	A459	cell	
line
In	vivo-jetPEI Decreased	tumor	size,	minimal	change	on	
blood	chemistry	or	cytokine	release
[145]
miR-34a-5p	(synthetic) Intramuscular
H460	or	H1299	cell	line
NOV340	(Liposomal	
nanoparticle)
Sensitized	tumor	to	irradiation [146]
miR-34a-5p	and	let-7b-
5p	(synthetic)
Kras/p53	mutant,	Cre-	
adenoviral activated
NOV340	(liposomal	
nanoparticle)
Combination	of	miR-34a-5p	and	let-7c-
5p	reduced	tumor	burden,	decreased	
proliferation,	and	increased	survival	with	
minimal	cytokine	induction
[140]
anti-miR-21-5p	
(synthetic)
Subcutaneous	A549	
cell line
QTsome	(cationic	lipids) Stable	tumor	growth	or	tumor	regression	
after	treatment,	increased	survival
[133]
anti-miR-183-5p	
(synthetic)
Subcutaneous	
A549-LUC-GFP
Adenovirus	(intra-tumoral	
injection)
Decreased tumor growth as measured by 
luminescence
[134]
miR-206-3p-agomir	
(synthetic)
Subcutaneous	A549	
cell line
No	vehicle	mentioned	
(intra-tumoral	injection)
Decreased tumor volume and formation 
of	intra-tumoral	capillary	tubes,	and	
increased apoptosis
[82]
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experienced	 immune-related	 adverse	 effects	 where	multiple	 deaths	
also	occurred	with	complex	and	uncertain	causes.	The	most	common	
adverse	effects	were	fever,	fatigue,	nausea,	diarrhea,	and	vomiting,	and	
laboratory	abnormalities	 included	 lymphopenia,	neutropenia,	 and	 in-
creased	AST	among	others.	The	study	does	not	distinguish	whether	the	
toxicity	resulted	from	the	RNA	or	the	liposomal	carrier,	however,	both	
components	have	shown	immune	toxicities	 in	previous	studies.148,149 
The	immune-related	toxicity	suggests	that	more	studies	are	warranted	
to	understand	the	effect	of	miRNA	therapies	and	the	carriers	on	the	
immune system. The termination of this trial reiterates the importance 
of safety study in addition to efficacy during drug development.
9  | CONCLUSIONS AND PERSPECTIVES
Functional	miRNAs	derived	 from	 the	human	genome	are	 critical	
factors	 in	 posttranscriptional	 regulation	 of	 target	 gene	 expres-
sion	 underlying	 many	 cellular	 processes,	 including	 metabolism,	
proliferation,	 apoptosis,	 and	 disease	 initiation	 and	 progression.	
Uncontrolled	NSCLC	cell	growth	and	tumor	development	is	asso-
ciated	with	dysregulated	miRNA	expression	in	addition	to	the	al-
terations	of	proteins	and	signaling	pathways,	among	which	tumor	
suppressive	miRNAs	are	generally	downregulated	and	tumor	pro-
motive	 miRNAs	 are	 commonly	 upregulated.	 With	 the	 improved	
understanding	 of	 miRNA	 biology	 in	 NSCLC,	 new	 miRNA-based	
therapies	 are	 under	 active	 investigations,	 in	 particular,	 the	 res-
toration	 of	 tumor	 suppressive	 miRNAs	 and	 inhibition	 of	 tumor	
promotive	 miRNAs.	 Nevertheless,	 many	 challenges	 remain	 for	
the	development	of	new	therapeutics.	Although	a	number	of	RNA	
drugs	 have	 been	 approved	 for	 clinical	 practice,142 the pharma-
cokinetic	and	pharmacodynamic	properties	of	RNA	molecules	are	
still	of	concern	since	RNA	molecules	are	generally	susceptible	to	
serum	RNases	and	cannot	pass	freely	through	cell	membrane	bar-
riers. Chemical modifications and formulation with biocompatible 
lipids or polymers have proven useful for improving the metabolic 
stability	and	delivery	of	RNA	therapeutics.	As	chemical	modifica-
tions	undoubtedly	lead	to	different	RNA	folding,	stability,	biologic	
activity,	and	safety	profiles,	there	are	growing	interests	in	produc-
ing	biologic	or	recombinant	RNA	molecules	in	living	cells	for	RNA	
research	 and	 drug	 development,141,142 similar as the success of 
protein-based	therapeutic	modalities.	Improved	formulations	with	
lipid	or	polymer-based	drug	delivery	systems	may	aid	 in	protect-
ing	the	RNA	from	degradation	or	recognition	by	the	immune	sys-
tem.	In	any	case,	evidence	is	required	to	address	two	fundamental	
questions:	whether	 the	drug	 is	effective	against	 the	disease	and	
whether	 the	 drug	 is	 safe	 for	 the	 patients,	which	warrants	more	
extensive	studies.
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